The Department of Health made the submission, supported the evaluation, waived related cost recovery fees for itself, attended the PBAC meetings at which it has been considered and presumably participated in the discussion, wrote the outcome and managed the listing process. How is this not deeply problematic? …
A deeply problematic situation caused by officials making it up as they go
July 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Pfizer commissioned polling finds strong public support for investing in the PBS
November 9, 2026 - - Latest News -
Pfizer confirms Ben Fitzsimmons as Australia and New Zealand chief
November 9, 2026 - - Latest News -
Coalition edges ahead in New Zealand as Stephenson returns and Pharmac pledges await the 'specials'
November 9, 2026 - - Latest News -
Celairis launches with plan to end the region's place at the rear of the launch queue
November 9, 2026 -